Tier 1 — highest

Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults

Meryl S LeBoff, Sharon H Chou, Kristin A Ratliff, Nancy R Cook, Bharti Khurana, Eunjung Kim, Peggy M Cawthon, Douglas C Bauer, Dennis Black, J Chris Gallagher, I-Min Lee, Julie E Buring, JoAnn E Manson
The New England journal of medicine 2022 387(4):299-309

Bibliography

PubMed
PMID 35939577
PubMed Central
PMC9716639
DOI
10.1056/NEJMoa2202106
Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Support is recorded from NCI NIH HHS, NCCIH NIH HHS, NIAMS NIH HHS, NIA NIH HHS. See the original publication for grant and material-support details.
Competing interests
A competing-interest declaration is not available in the indexed abstract or accessible disclosure metadata.

Study snapshot

DesignRandomized controlled clinical trial
ModelHuman participants
Sample25,871 VITAL participants
InterventionVitamin D3 2,000 IU/day or placebo
DurationMedian 5.3 years
EndpointsTotal fractures; Nonvertebral fractures; Hip fractures

What the study showed, in plain terms

This publication examines total fractures, nonvertebral fractures, hip fractures. Study population or evidence base: 25,871 VITAL participants. Intervention or exposure: Vitamin D3 2,000 IU/day or placebo.

Key findings

Vitamin D3 did not significantly reduce total, nonvertebral or hip fractures in this generally healthy older population.

What this study can and cannot tell us

Participants were not recruited for deficiency, osteoporosis or low bone mass. This is a VITAL ancillary study, not an independent trial population.

Related papers in the corpus

Tier 1
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
JoAnn E Manson et al. · The New England journal of medicine · 2019
Tier 1
Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial
Jill Hahn et al. · BMJ (Clinical research ed.) · 2022
Tier 1
Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial
Karen H Costenbader et al. · Arthritis & rheumatology (Hoboken, N.J.) · 2024
Tier 1
Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial
Olivia I Okereke et al. · JAMA · 2020
Tier 1
Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial
Deirdre K Tobias et al. · Nature communications · 2025
Tier 1
Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial
Yanbin Dong et al. · Nutrients · 2022

Citation network

Articles citing this research paper

3 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Biohack Blueprint Research